January 30th 2023
Results from the phase 1/2 CodeBreaK 100 trial indicate that sotorasib yields positive anticancer activity and safety in patients with pancreatic cancer harboring KRAS p.G12C mutations.
January 21st 2023
Individuals With Pathogenic ATM Variant Have an Increased Lifetime Risk of Developing Pancreatic CancerOctober 5th 2021
Research of family registries found that individuals with a germline pathogenic ATM variant gene had greater lifetime risk of developing pancreatic cancer than individuals without the gene.
FDA Grants New 510(k) Clearance to RenovoCath Delivery System for Targeted Treatment of Solid TumorsSeptember 7th 2021
RenovoCath, which was granted a new 510(k) clearance by the FDA, distributes chemotherapy directly to solid tumors via the arteries, opening avenues for a more targeted treatment.
Phase 3 Study Explores Pamrevlumab for Unresectable LAPCFebruary 17th 2021
The first-in-class inhibitor of connective tissue growth factor activity is being explored in combination with neoadjuvant gemcitabine and nab-paclitaxel as a potential method for downgrading unresectable locally advanced pancreatic cancer.
Phase 3 TRYbeCA-1 Trial in Second-Line Pancreatic Cancer Will Continue to Final AnalysisFebruary 9th 2021
Per a planned interim superiority analysis conducted by an independent data monitoring committee, a trial of Eryaspace will continue without modification with final results anticipated later this year.
Lymph Node Metastases, Additional Organ Resection Associated With Increased Recurrence Risk for PNETsJanuary 26th 2021
A study found a number of factors associated with increased recurrence risk for patients with locally advanced pancreatic neuroendocrine tumors following surgical resection, including sex, lymph node metastases, and resection of other organs with tumor involvement.
FDA Places Clinical Hold on Phase 1/2 Trial Evaluating BPX-601 for Metastatic Pancreatic, Prostate CancerDecember 7th 2020
The FDA placed a clinical hold on patient enrollment and dosing for the ongoing phase 1/2 dose-escalation clinical trial evaluating BPX-601 in patients with previously treated metastatic pancreatic or prostate cancer.
Maintenance Olaparib May Be Cost-Effective for BRCA-Mutated Metastatic Pancreatic CancerNovember 19th 2020
Study results suggested that maintenance olaparib (Lynparza) is potentially cost-effective compared with placebo for patients with metastatic pancreatic cancer and a germline BRCA mutation.
Adjuvant Chemo After FOLFIRINOX Treatment Fails to Improve Survival in Pancreatic CancerSeptember 16th 2020
This study found that adjuvant chemotherapy in patients with resected pancreatic cancer after treatment with neoadjuvant FOLFIRINOX was not associated with improved overall survival.
Improved Risk Models Identify People at Higher than Normal Risk of Pancreatic CancerMay 2nd 2020
Researchers demonstrated that risk models that include established clinical, genetic, and circulating factors are better able to identify people at significantly higher than normal risk of pancreatic cancer over those using clinical factors alone.
Outcomes of the SARS-CoV-2 Infection in Patients with Cancer Treated in ChinaMarch 27th 2020
Researchers reported on the incidence and outcomes of the SARS-CoV-2 infection, which has been linked to COVID-19, in patients with cancer who were treated at a tertiary cancer institution in Wuhan, China.
Stereotactic Body Radiation Therapy Improves OS for Locally Advanced Pancreatic CancerMarch 10th 2020
An international systematic review and meta-analysis indicated that stereotactic body radiation therapy compared to conventionally fractioned radiation therapy with concurrent chemotherapy may offer a modest improvement in OS with a more favorable toxicity profile.
Eileen M. O’Reilly, MD, on the Challenges of Treating Patients with Pancreatic CancerJanuary 27th 2020
The medical oncologist from Memorial Sloan Kettering Cancer Center discussed challenges in treating patients with pancreatic center, and also the challenge of obtaining effective drugs in the clinical setting.
Can PARP Inhibitors and Immune Checkpoint Inhibitors Improve Outcomes in Ovarian Cancer?August 23rd 2019
A new phase 1a/b study examined a total of 49 patients with solid tumors, including 34 with ovarian, fallopian tube, or primary peritoneal cancer, treated with a combination of the PARP 1/2 inhibitor pamiparib and the anti-PD-1 monoclonal antibody tislelizumab in several dose escalation cohorts.